Effect of Rifampin on the Pharmacokinetics of BAY73-4506

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Neoplasms
Interventions
DRUG

Regorafenib (BAY73-4506) + rifampin

Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.

Trial Locations (1)

78744

Austin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY